Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAIC with FOLFOX in Advanced HCC Post-ICI/Antiangiogenic Failure
NCT05718492Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Oct 2022
- Primary completion
- Oct 2025
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
Open-label, single-arm trial of oxaliplatin, folinic acid and fluorouracil in hepatocellular carcinoma (HCC), sponsored by Sun Yat-sen University. Primary endpoints: Objective Response Rate at 2 years and Progression Free Survival at 2 years. Started Oct 2022; status: recruiting.
02
Drugs
oxaliplatinfolinic acidfluorouracil
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05718492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05718492.